CrisprBits Secures $3 Million Pre-Series A Funding for Rapid Drug-Resistant Infection Tests

Biotechnology

28 July 2026 at 9:24 pm

CrisprBits Secures $3 Million Pre-Series A Funding for Rapid Drug-Resistant Infection Tests

HyperFast News

Summary

CrisprBits, founded in 2020, is developing CRISPR-based technology to create faster diagnostic tests for drug-resistant infections and other applications. The company recently raised $3 million in a pre-Series A round and operates three platforms: PathCrisp for diagnostics, EdiCrisp for gene editing, and CurieCrisp for pre-clinical work.

Select what you want to create

Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.

FAQ

Newsroom FAQs

About the public HyperFast News news feed powered by NewsEngine.